Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Operating income | -$747K | -$1.28M | -$11.9M |
| Net income | -$778K | -$1.39M | -$6.00M |
| EPS (diluted) | -$0.17 | -$0.18 | -$0.55 |
| Fiscal year | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Operating cash flow | -$628K | -$734K | -$8.93M |
| Capital expenditures | — | — | $57.3K |
| Free cash flow | — | — | -$8.98M |
| Fiscal year | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Cash & equivalents | $410K | $3.46K | $1.64M |
| Total assets | $422K | $13.1K | $164M |
| Total liabilities | $390K | $1.37M | $10.8M |
| Shareholders' equity | $31.9K | -$1.36M | $153M |
| Retained earnings | -$3.00M | -$4.39M | -$10.4M |
| Shares (wtd avg diluted) | 4.60M | 7.90M | 10.9M |
Every figure is extracted from Apimeds Pharmaceuticals US, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.